@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma
@EricPFierce: Novartis says construction delay of Russian plant no big deal, technical changes and not tied to sanctions. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Sanofi wins kudos for airing bribery probe. Phase II? Take to social media. Article | Follow @CarlyHFierce
> Novo Nordisk ($NVO) is on the brink of announcing an initial public offering for its information technology unit, NNIT, a Danish newspaper reports; the drugmaker said in January that it was considering an NNIT spinoff. Report
> U.S.-based Alexion Pharmaceuticals ($ALXN) says it's weighing a move of its European headquarters to Zurich, as part of a plan to expand operations in the country. Report
> The Belgian biotech Galapagos wooed its new chief financial officer, Bart Filius, away from his post as VP of Sanofi Europe. Report
> AstraZeneca's ($AZN) new head of investor relations says he's looking to set up an IR beachfront in the U.S. Report
> Retrophin ($RTRX) agreed to sell off some "non-core" assets, including the oxytocin nasal spray Syntocinon, to Turing Pharmaceuticals for $3 million, plus debt assumption. Release
Medical Device News
@FierceMedDev: Who are today's leading women in med tech? Check out our top women in medical devices list to find out. Special report | Follow @FierceMedDev
@VarunSaxena2: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2
@EmilyWFierce: $COV recalled some defibrillator electrodes made by $PHG. Story from MassDevice | Follow @EmilyWFierce
@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story | Follow @MichaelGFierce
> In latest M&A news, ConvaTec is up for sale. Story
> St. Jude posts modest gains in Q3 financials led by new products. Article
> Beyond glucose: Developing a diagnostic test for fructose intolerance. More
Biotech News
@FierceBiotech: Meet some of the revolutionaries in biotech R&D. Report | Follow @FierceBiotech
@JohnCFierce: AbbVie to Shire: Maybe we should reconsider that $54B merger deal after all - $SHPG down 27%. Article | Follow @JohnCFierce
@DamianFierce: Fantastically timed press release: "Shire Announces the Organize Your Stuff Contest Winners." Release | Follow @DamianFierce
@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce
> Selecta banks $20M for trial work, inks a pact with Sanofi on diabetes. Story
> Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen. More
> DNAtrix pockets $20M to get its cancer-fighting virus into Phase III. Article
Drug Delivery News
> Robert Langer talks science, business and how they intersect. More
> Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story
> Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. Report
> Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients. Item
> Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging. Article
Diagnostics News
> Gene sequencing helps Northwestern team diagnose one cause of epilepsy. More
> Exact Sciences nails coveted Medicare coverage for colon cancer DNA test. News
> SomaLogic, CO hospital to develop biomarkers/Dx tests for childhood diseases. Story
> British startup finishes quick and easy Ebola test. Report
> Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. Article
Pharma Marketing News
> Teva's SCOTUS appeal is here. But how much can the outcome really affect Copaxone's market share? More
> World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Read
> Looking 'beyond the pill'? Start with an app--and then follow this to-do list. Story
> Can Amgen's marketing muscle vault its Humira biosim ahead of rivals? More
> Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. Article
And Finally... How a cooling cap could change breast cancer treatment. Report